The US Food and Drug Administration’s new draft guidance on investigational new drug application submissions for individualized gene therapies focuses largely on helping sponsors initiate early interaction with the agency and does not address regulatory requirements for clinical trials or commercialization pathways, making the new document a relatively small down payment on FDA’s more than year and a half old promise to quickly put together policy on how to handle applications for personalized medicine.
US FDA’s New ‘N of 1’ Guidance Essentially A Down Payment On Critical Advice
Draft guidance will help sponsor-investigators working on individualized gene therapies. The focus on basic administrative and procedural aspects of interaction with the FDA leaves many policy and commercialization questions about how these personalized investigational products should be studied unanswered.
More from Cell & Gene Therapies
More from Advanced Technologies
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.
• By
US FDA Commissioner nominee Martin Makary is being embraced by industry, and Senate Democrats, as a more traditional pick than other Trump Administration nominees, but the Make America Healthy Again agenda still is clearly coming to the agency.
• By
Not all companies will be able to access joint scientific consultations under the EU Health Technology Assessment Regulation, but success is still possible for those that engage with national agencies early on, says EUCOPE’s Alexander Natz.